armata investors

Press Releases

AmpliPhi Biosciences to Hold Business Update Conference Call on May 15

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update conference call on Monday, May 15, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

Live Call:

    U.S. 877-866-5534
      International 346-406-0930
      Passcode 20313217
Live Webcast:    

AmpliPhi IR Website


The webcast replay will be available approximately 2 hours


after completion of the call and will be archived for 30 days.

Replay:     U.S. 855-859-2056
      International 404-537-3406
      Passcode 20313217

The replay will be available for 48 hours starting approximately


2 hours after completion of the call.


About AmpliPhi Biosciences

AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of S. aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.



At the Company: 
AmpliPhi Biosciences
Matthew Dansey, (858) 800-4869 
Investor Relations: 
Jody Cain, (310) 691-7100